Several announcements this week made plain that maintaining U.S. leadership in biotechnology is a top administration priority, and that AI is the tool it intends to use to secure it. Across OSTP, HHS, and FDA, the same themes recurred: compressing development timelines, closing gaps in foundational research, and reengineering the federal science funding for the AI age.
“Golden Age” Report on Federal Funding: On July 21, Office of Science and Technology Policy (OSTP) Director Michael Kratsios released Science: A New Golden Age, billed as the first comprehensive rethinking of the U.S. science enterprise since Vannevar Bush’s Science: The Endless Frontier over 80 years ago, paired with an FY2028 R&D Priorities Memorandum issued with OMB Director Russ Vought that directs federal agencies to submit implementation action plans within 90 days and fold the guidance into their FY2028 budgets. AI is the organizing principle throughout with the report calling for reengineering research infrastructure for the AI age. The Genesis Mission, the administration’s flagship effort to double the productivity of American science within a decade, is a central priority across agencies. The report presents life sciences as a primary example of stagnation, with breakthroughs slowing and drug approvals flatlining despite decades of rising funding, to argue that money alone hasn’t delivered and that the standard NIH R01 model leaves gaps in the mid-scale, engineering-intensive research that neither academia nor industry reliably funds. The memo instructs agencies to prioritize foundational research in the biological sciences and notably favors “biological sciences” over the broader “life sciences” category. It also proposes new institutional models (X-Labs, FROs, expanded ARPA-style entities) targeting the platform-technology gap in basic biology, and grantmaking reforms (golden tickets, fast grants, long-horizon Pioneer Award-style grants) that would reshape how biomedical researchers compete for dollars.
Focus on Biotech in House Science FY27 R&D hearing with OSTP Director Kratsios: The House Committee on Science, Space, and Technology held a hearing on Wednesday, July 22, where OSTP Director Kratsios testified on the administration’s FY2027 research and technology priorities. Chairman Babin framed biotechnology alongside AI, quantum, and advanced manufacturing as one of the defining technologies of the century, and the sector featured prominently throughout the discussion. Members from both parties probed how federal policy can strengthen the domestic biotech ecosystem, though several raised concerns that the administration’s agency restructuring, staff reductions, and funding cuts have weakened US competitiveness and inadvertently ceded ground to China. Two themes dominated the biotech discussion: workforce and manufacturing. On workforce, members discussed aligning federal training and grant programs with industry needs, with Kratsios pointing to NIH biotech-specific grant and fellowship programs as a vehicle. On manufacturing, members invoked NSCEB findings that China controls roughly 90% of active pharmaceutical ingredient production, highlighting recently introduced legislation directing DOE to build domestic bio-industrial manufacturing capacity.
HHS joins Genesis Mission with AI-driven biomedical research push: On July 22, HHS announced it is aligning capabilities across the Department to support the administration’s Genesis Mission. The centerpiece of HHS’s participation is the NIH-led Bio Genesis Mission, which is endeavoring to modernize the biomedical research ecosystem and cut in half the time it takes for scientific discoveries to reach patients by applying AI tools to large, complex datasets across scientific disciplines. HHS will also partner with OSTP to launch a series of National Science and Technology Challenges inviting the research community to apply next-generation AI to urgent health problems, including identifying the root causes of chronic disease, plus additional challenges on pediatric cancer and drug discovery and development. The drug discovery challenge aims to use AI to shorten development timelines, identify promising therapeutic targets, and bring treatments to patients faster. NIH, FDA, and ARPA-H will contribute biomedical research, genomics, public health, and safety data to power the effort.
FDA Extends Comment Deadline for Expedited IND Pilot to August 24: FDA has extended the public comment period for its proposed Expedited Investigational New Drug (IND) Pilot Program through August 24, 2026, giving stakeholders an additional month to weigh in. The pilot is one of the centerpiece initiatives under HHS’s “Operation Trialblazer,” a broader push to compress drug development timelines from the IND stage forward. The program would establish a network of qualified research institutions that would partner with sponsors to develop and review protocols for first-in-human clinical trials intended for IND submission. These institutions would assess and make recommendations on the pharmacology and toxicology, clinical, and chemistry, manufacturing and controls (CMC) components of the Phase 1 submission, though participation would remain voluntary and the recommendations advisory. FDA has also floated a rolling submission platform that would let the agency resolve potential deficiencies earlier and issue a “safe to proceed” letter sooner. MassBio will be commenting encouraging prompt action to support early-stage companies for whom speed to first-in-human is a critical value-inflection and financing milestone.
